Acquired sensory ganglionopathy

Acquired sensory ganglionopathy (also known as acquired sensory neuronopathy or dorsal root ganglionopathy) is a rare neurological disorder characterized by damage to the sensory neurons located in the dorsal root ganglia and, in some cases, the trigeminal ganglia. Unlike hereditary forms, this condition is acquired during a person's lifetime and can be associated with autoimmune disorders (such as Sjögren syndrome), paraneoplastic syndromes (often linked to anti-Hu antibodies in the setting of small cell lung cancer), infections (such as HIV), toxic exposures (including certain chemotherapy agents like cisplatin and pyridoxine toxicity), or it may be idiopathic with no identifiable cause. The disease primarily affects the peripheral sensory nervous system. Because the cell bodies of sensory neurons are directly damaged, the condition tends to produce a distinctive non-length-dependent pattern of sensory loss, meaning symptoms can affect proximal and distal areas asymmetrically. Key clinical features include progressive sensory ataxia (impaired coordination due to loss of proprioception), widespread numbness and paresthesias, painful dysesthesias, and pseudoathetoid movements of the hands. Patients often experience significant difficulty with balance and fine motor tasks due to the loss of deep sensory modalities such as vibration and joint position sense. Tendon reflexes are typically absent or markedly reduced. There is no definitive cure for acquired sensory ganglionopathy. Treatment is directed at the underlying cause when one is identified — for example, immunosuppressive therapy for autoimmune-associated forms, or treatment of the underlying malignancy in paraneoplastic cases. Intravenous immunoglobulin (IVIg), corticosteroids, and plasma exchange have been used with variable success, particularly in immune-mediated cases, though early intervention appears to yield better outcomes. Symptomatic management includes neuropathic pain medications (such as gabapentin, pregabalin, or duloxetine), physical therapy, and occupational therapy to help maintain function and mobility. The prognosis varies depending on the etiology, but neuronal loss is often irreversible, making early diagnosis and treatment critical.

Common questions about Acquired sensory ganglionopathy